TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19350213
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous glucose monitoring (CGMS) with norepinephrine therapy
Study: 19350213
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous glucose monitoring (CGMS) without norepinephrine therapy
Study: 19350213
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous glucose monitoring (CGMS)
Study: 19358725
Drug: abacavir sulfate/lamivudine/zidovudine
Normalized name: Abacavir Sulfate/Lamivudine/Zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: abacavir sulfate/lamivudine/zidovudine (ABC/3TC/ZDV) twice-daily
Study: 19358725
Drug: atazanavir (ATV)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: atazanavir (ATV) once-daily plus lamivudine/zidovudine (3TC/ZDV) twice-daily
Study: 19364933
Drug: Interferon beta-daclizumab
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta-daclizumab combination therapy (months 0-5.5)
Study: 19364933
Drug: Daclizumab monotherapy
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab monotherapy (months 6.5-15.5)
Study: 19364933
Drug: Interferon beta
Normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon beta monotherapy
Study: 19364933
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg) as an intravenous infusion every 4 weeks
Study: 19365012
Drug: Topical bevacizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bevacizumab, 1.0% for 3 weeks
Study: 19366446
Drug: Compassionate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassionate treatment with tumor-specific frequencies
Study: 19369238
Drug: Sublingual application
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual application of 0.8 mg GTN
Study: 19369372
Drug: Golden Rice
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golden Rice (65-98 g servings containing 0.99-1.53 mg beta-carotene) with 10 g butter
Study: 19369372
Drug: [13C10]retinyl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: [13C10]retinyl acetate reference dose (0.4-1.0 mg) in oil
Study: 19371392
Drug: Bortezomib 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.3 mg/m² (i.v. bolus days 1, 4, 8, 11) for up to eight 21-day cycles (C)
Study: 19375217
Drug: High-dose exogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally for 1 week, 1 month, or until disease progression.
Study: 19375217
Drug: High-dose exogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exogenous testosterone (three times the standard replacement dose) administered transdermally.
Study: 19376495
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.5 mg) administered as 3 consecutive monthly injections, followed by a variable-dosing regimen based on OCT criteria.
Study: 19377385
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy of OAC, aspirin and clopidogrel
Study: 19380866
Drug: Bortezomib plus
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib plus chemotherapy
Study: 19383032
Drug: Rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (8 mg q.d.)
Study: 19386738
Drug: Iron excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron excretion in men
Study: 19386738
Drug: Iron excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron excretion in menstruating women
Study: 19386738
Drug: Iron excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron excretion in postmenopausal women
Study: 19386738
Drug: Iron excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron excretion in menstruating women (excluding hormonal contraceptive users)
Study: 19389332
Drug: Lithium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium administration for 4 weeks
Study: 19394037
Drug: High-dose extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose extended-release methylphenidate (OROS MPH) up to 1.5 mg/kg/d
Study: 19394037
Drug: High-dose extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose extended-release methylphenidate (OROS MPH)
Study: 19398716
Drug: Ezatiostat hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat hydrochloride (TLK199 tablets) at dose levels of 200 to 6000 mg/day
Study: 19398716
Drug: Ezatiostat hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat hydrochloride (TLK199 tablets)
Study: 19399550
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative oral feeding (liquid diet on POD 2, soft diet on POD 3)
Study: 19399946
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NT-proBNP, PetCO2, and clinical assessment
Study: 19399946
Drug: NT-proBNP in
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP in combination with clinical assessment
Study: 19399946
Drug: NT-proBNP >
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP > or = 2000 pg/mL and PetCO2 < or = 4 kPa
Study: 19400961
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) offered in addition to telephone counselling
Study: 19400961
Drug: No offer
Approvals — FDA: no, EMA: no, PMDA: no
Description: No offer of Nicotine Replacement Therapy (NRT)
Study: 19402886
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (CEE) at a dosage of 0.625 mg/d for 1 year
Study: 19403641
Drug: High-fructose diet
Normalized name: High Fructose Corn Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fructose diet (3.5 g x kg FFM(-1) x d(-1), +35% energy intake)
Study: 19404953
Drug: Moderate dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dosage of prednisone (0.15-0.4 mg/kg/day)
Study: 19415121
Drug: Customized therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customized therapy based on BRCA1 mRNA levels
Study: 19415121
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with low BRCA1
Study: 19415121
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with intermediate BRCA1
Study: 19415121
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with high BRCA1
Study: 19419474
Drug: Topical imiquimod
Normalized name: imiquimod Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical imiquimod applied three to seven times per week for 16 weeks
Study: 19421322
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 13 weeks
Study: 19439093
Drug: Ezatiostat hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat hydrochloride liposomes for injection (IV) at 5 dose levels (50, 100, 200, 400, and 600 mg/m2) on days 1 to 5 of a 14-day cycle
Study: 19439093
Drug: Ezatiostat hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat hydrochloride liposomes for injection (IV) at 600 mg/m2 on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle
Study: 19439093
Drug: Ezatiostat hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Ezatiostat (DB05460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezatiostat hydrochloride liposomes for injection
Study: 19440083
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/d (smokers)
Study: 19440083
Drug: Olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 20 mg/d (smokers)
Study: 19440083
Drug: Olanzapine 40
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 40 mg/d (smokers)
Study: 19440083
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/d (nonsmokers)
Study: 19440083
Drug: Olanzapine 20
Normalized name: olanzapine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 20 mg/d (nonsmokers)
Study: 19440083
Drug: Olanzapine 40
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 40 mg/d (nonsmokers)
Study: 19440083
Drug: Olanzapine 40
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 40 mg/d (African Americans)
Study: 19440083
Drug: Olanzapine 40
Normalized name: olanzapine 405 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 40 mg/d (Whites)
Study: 19443656
Drug: Adoptive immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adoptive immunotherapy with peripheral blood-derived virus-specific cytotoxic T lymphocytes (CTLs) expanded from CB T cells.
Study: 19454532
Drug: Alemtuzumab (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (0.3 mg/kg/day for 4 days)
Study: 19457240
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) (DrotAA) administered within 24 hours of first sepsis-induced organ dysfunction
Study: 19457240
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) (DrotAA) administered after 24 hours of first sepsis-induced organ dysfunction
Study: 19457245
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with CPT-11, 5-FU, and LV for 12 weeks (preoperative phase)
Study: 19457245
Drug: Postoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative treatment with the same regimen (CPT-11, 5-FU, and LV) for 12 weeks
Study: 19457253
Drug: Control (before
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (before administration of tremelimumab)
Study: 19459850
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with three peptides (TTK, LY6K, IMP-3) at 1 mg each, administered intradermally with 1 mL of incomplete Freund's adjuvant weekly for 5 weeks
Study: 19463441
Drug: Biodegradable polymer-coated
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biodegradable polymer-coated sirolimus-eluting stent (Excel) with 6-month dual antiplatelet therapy
Study: 19466962
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied three times weekly for up to 16 weeks
Study: 19467341
Drug: F/S bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: F/S bid plus Zileuton 600 mg qid
Study: 19470620
Drug: Cinacalcet (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (titrated from 30 mg twice daily to 90 mg four times daily during a titration phase of 2-16 weeks)
Study: 19470631
Drug: Anastrozole, 1
Normalized name: Anastrozole, 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole, 1 mg, daily for 6 months
Study: 19471019
Drug: Lenalidomide 30
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 30 mg/day once daily (days 1-21 every 28 days)
Study: 19479077
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment at maintenance dose
Study: 19479315
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine (LDD) Tc-99m-mibi gated-SPECT
Study: 19483644
Drug: PSA: 154-163
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA: 154-163 (155L) vaccination with Montanide ISA-51, 1 mg, given subcutaneously 7 times on weeks 0, 2, 4, 6, 10, 14, and 18.
Study: 19485285
Drug: Alpha-1 adrenergic
Normalized name: Alpha-1 adrenergic receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-1 adrenergic blocker (A1AB) use
Study: 19488737
Drug: Hyperglycaemia clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycaemia clamp study (glucose at 11 mmol/l)
Study: 19492661
Drug: Intradermal skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal skin testing (ST)
Study: 19492661
Drug: Epinephrine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.2 mL of a 1:1,000 dilution) intramuscularly
Study: 19493369
Drug: Citalopram up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram up to 60 mg/day for up to 14 weeks
Study: 19494218
Drug: Anakinra (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (recombinant interleukin-1-receptor antagonist)
Study: 19496252
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium
Study: 19497063
Drug: Treatment options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment options reviewed
Study: 19498019
Drug: Bortezomib once
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib once weekly (0.7-1.6 mg/m²; days 1, 8, 15, and 22; 35-day cycles)
Study: 19498019
Drug: Bortezomib twice
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib twice weekly (0.7-1.3 mg/m²; days 1, 4, 8, and 11; 21-day cycles)
Study: 19498019
Drug: Both once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both once-weekly and twice-weekly bortezomib
Study: 19502645
Drug: Prompt revascularization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt revascularization with intensive medical therapy
Study: 19502645
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy in CABG stratum
Study: 19502645
Drug: Insulin-provision group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-provision group
Study: 19502645
Drug: Insulin-sensitization group
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-sensitization group
Study: 19505676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (contralateral glaucomatous eyes receiving antiglaucoma medications)
Study: 19506189
Drug: 15-mL bottle
Normalized name: bottlebrush pollen extract 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mL bottle
Study: 19506189
Drug: 2.5-mL bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-mL bottle
Study: 19507806
Drug: OROS hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OROS hydromorphone (individualized doses), administered once daily.
Study: 19508731
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d
Study: 19508997
Drug: Higher intake
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher intake of DHA (>=64.0 mg/day)
Study: 19508997
Drug: Higher intake
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher intake of EPA (>=42.3 mg/day)
Study: 19509175
Drug: Pazopanib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 300 mg twice daily
Study: 19509175
Drug: Pazopanib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib (various doses)
Study: 19515473
Drug: Home BP
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home BP measured 3 times daily for 1 week using a validated oscillometric monitor.
Study: 19520420
Drug: PLD 30
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 30 mg/m² followed by carboplatin AUC 5 mg/mL/minute every 4 weeks
Study: 19524963
Drug: Denosumab (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (180 mg subcutaneous every 4 weeks or every 12 weeks)
Study: 19524963
Drug: Intravenous bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bisphosphonates (every 4 weeks)
Study: 19542735
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (ATG) 120 mg injections every 4-8 weeks
Study: 19546056
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous pramlintide infusion (CSPI) at 9 microg/h with premeal bolus doses starting at 15 microg and titrated to 60 microg
Study: 19549740
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (NAL-GLU, 150 microg/kg sc) followed by GnRH doses of 25, 75, 250, or 750 ng/kg iv every 4 h
Study: 19549995
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing (53% overall)
Study: 19549995
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics prescribed (control group)
Study: 19553641
Drug: Olaparib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (600 mg twice daily)
Study: 19553641
Drug: Olaparib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (10 mg daily for 2 of every 3 weeks)
Study: 19555842
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of troponin T and copeptin
Study: 19555842
Drug: Copeptin <14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin <14 pmol/l and troponin T < or =0.01 microg/l
Study: 19556425
Drug: Immunotherapy (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (autologous leukemia cells with GM-CSF-secreting K562 cells)
Study: 19556425
Drug: Immunotherapy-treated patients
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy-treated patients (28 patients)
Study: 19556425
Drug: Decrease in
Normalized name: Titanium Dioxide 7.2 g in 100 mL / Zinc Oxide 4 g in 100 mL TOPICAL LIQUID [Decree Daily Shield Broad Spectrum SPF 30 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease in WT1 transcripts after first immunotherapy dose
Study: 19562254
Drug: Erlotinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib plus sirolimus (150 mg and 5 mg for patients not on concurrent CYP3A-inducing anti-epileptics; 450 mg and 10 mg for patients on EIAEDS)
Study: 19565495
Drug: Anti-TNF monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF monoclonal antibody therapy (infliximab, adalimumab)
Study: 19565495
Drug: Anti-TNF monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-TNF monoclonal antibody therapy (etanercept)
Study: 19569973
Drug: 90 microg
Normalized name: Linaclotide 290 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 microg H5N1 A/Vietnam/1203/04 vaccine
Study: 19569973
Drug: 120 microg
Normalized name: Betamethasone 120 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 microg H5N1 A/Vietnam/1203/04 vaccine
Study: 19569973
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg H5N1 A/Vietnam/1203/04 vaccine
Study: 19573495
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral lorazepam
Study: 19576329
Drug: Guideline-recommended therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended therapies (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and beta-blocker use)
Study: 19576329
Drug: All guideline-recommended
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All guideline-recommended cardiac medications prescribed at discharge
Study: 19581810
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment with oral lansoprazole
Study: 19584400
Drug: ABVE-PC (doxorubicin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVE-PC (doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide) administered every 21 days
Study: 19586800
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment)
Study: 19586800
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day)
Study: 19587341
Drug: Intraarticular delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular delivery of a TNF-alpha antagonist via an AAV type 2 delivery system
Study: 19587341
Drug: Concurrent anti-TNF-alpha
Normalized name: anti-interleukin-1.alpha. immunoglobulin G rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent anti-TNF-alpha therapy and other immunosuppressive therapy
Study: 19587528
Drug: Mtb72F/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mtb72F/AS02A vaccine (3 doses according to a 0-1-2 months schedule)